We aimed to explore the efficacy and safety of once-weekly trelagliptin 100 mg as an add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control. Patients with haemoglobin A1c (HbA1c) 7.5% to 10.0% who were receiving 8 to 40 units of insulin per day were randomized to receive, with insulin, trelagliptin 100 mg (A/A, n = 116) or placebo (P/A, n = 124) for a 12-week double-blind (DB) phase, after which all received trelagliptin for a 40-week open-label phase. Primary endpoints were HbA1c change from baseline to the end of the DB phase and adverse events (AEs). Once-weekly trelagliptin 100 mg therapy with insulin demonstrated a significant reduction in HbA1c. Long-term treatment was well-tolerated, with no clinically significant hypoglycaemia, suggesting that trelagliptin with insulin is a meaningful treatment option in this patient population.
| INTRODUCTION
The prevalence of type 2 diabetes mellitus (T2DM) in Japan has risen in recent decades from 6.6% in 1990 to 7.9% in 2010 and is expected to increase further, reaching 9.8% by 2030. 1 This has been attributed to an aging population 2 and to lifestyle factors associated with westernization, such as sedentary behaviour and obesity. 3, 4 Despite a comprehensive armamentarium of anti-diabetic medications, 5 the increasing prevalence of T2DM suggests that new treatments and regimens are still required.
Trelagliptin succinate (trelagliptin; Zafatek patients, including those with moderate renal impairment. 6 In Phase II and III studies, trelagliptin has demonstrated clinically and statistically significant improvements in glycaemic control, 7 non-inferiority to once-daily alogliptin, 8 long-term safety and a good tolerability profile, both as a monotherapy treatment option and in combination with an existing oral anti-diabetic drug (OAD). 9 Moreover, in a Phase III openlabel exploratory study, switching from a once-daily DPP-4 inhibitor (sitagliptin) to trelagliptin treatment had no major impact on glycaemic control or safety in T2DM patients. 10 To improve glycaemic control, insulin can be used as an alternative or add-on therapy in patients with inadequate glycaemic control who are undergoing treatment with an OAD, diet and exercise. 11, 12 Thus, this 2-phase multicentre study assessed the efficacy and safety of trelagliptin as an add-on therapy to insulin in patients with T2DM who are unable to achieve sufficient glycaemic control with insulin alone.
| Participants
Japanese T2DM patients aged ≥20 years with inadequate glycaemic control despite treatment with insulin were recruited. Patient eligibility criteria included haemoglobin A1c (HbA1c) level ≥7.5 and <10.0%
(≤10% variation from Week −6 to Week −2); fasting C-peptide value of ≥0.6 ng/mL (Week −6 and Week −2); daily insulin dose ≥8 and ≤40 units per day at a fixed dose and regimen; and fixed diet and exercise therapy. Please see Supporting Information (Materials and Methods) online for further details.
| Randomisation and study treatments
For the double-blind phase, eligible patients were randomized 1:1, using a permuted block schedule allocated to each site, to trelagliptin 100 mg QW with insulin (A/A group) or a placebo QW with insulin 
| Study endpoints and assessments
The primary efficacy endpoint was change in HbA1c from baseline to the end of the double-blind phase. Additional efficacy measures included change from baseline at each visit for HbA1c, and the proportion of patients who reached target HbA1c levels of <6%, <7%
or <8% at the end of the double-blind phase.
The primary safety endpoint was frequency and nature of treatment-emergent adverse events (TEAEs).
Other endpoints are discussed online in Supporting Information (Materials and Methods). Patients were assessed by the same investigator at each study visit.
| Statistical analyses
The total number of randomized patients was determined to be 125 per group in order to collect data from approximately 100 patients under treatment with the combination of trelagliptin and insulin preparations for 52 weeks, as required by the Japanese Guideline for Clinical Evaluation of Hypoglycemic Agents (revised draft), assuming a dropout rate of 20% during treatment. This also provided more than 90% power for the primary efficacy endpoint to detect the between-group difference of −0.4%, assuming the common standard deviation (SD) of 0.8% with a two-sided 5% significance level in a two-sample t-test.
All efficacy analyses were conducted on the full analysis set (FAS)
unless otherwise stated and the safety analysis was conducted on the safety analysis set. Additional details can be found online in Supporting Information (Materials and Methods).
| RESULTS
Of the 539 patients who signed informed consent, 240 were randomized to receive treatment in the double-blind phase (A/A group, n = 116; P/A group, n = 124) ( Figure S1 in File S1) and 231 received trelagliptin in the open-label phase (A/A group, n = 112; P/A group, n = 119). In total, 203 patients (A/A group, n = 100; P/A group, n = 103) completed both the double-blind phase and the open-label phase. All randomized patients were included in the FAS and safety analysis set.
The demographics and baseline patient characteristics were generally similar between groups (Table 1 ). More than 90% of patients fully complied with adherence to insulin during the screening period and the treatment period in both treatment groups. Further details can be found online in Supporting Information (Results).
| Efficacy
Based on an ANCOVA model with treatment group as a fixed effect (Table S3 in File S1). The proportion difference (95% CI) was 13.2% (6.06 to 20.40). Other endpoints are discussed online in Supporting Information (Results).
The mean change in glycaemic parameters from baseline to the end of the double-blind phase and end of trelagliptin treatment are detailed in Table S1 in File S1. The mean change in HbA1c from baseline to the end of the double-blind phase by sub-group is detailed in Table S2 in File S1. Mean change in HbA1c from baseline to Week 52 is depicted in Figure S2 in File S1.
| Safety
The incidence of TEAEs during the double-blind phase was comparable between the A/A and P/A groups (n = 51, 44.0%; n = 59, 47.6%, respectively) (Table S4 in File S1). TEAEs with an incidence of ≥2% in either treatment group (A/A vs P/A) were nasopharyngitis (7.8% vs 8.9%), hypoglycaemia (10.3% vs 8.9%) and upper respiratory tract inflammation (2.6% vs 4.0%) ( Table S5 in File S1). There were no deaths reported. A total of 4 patients (3.4%) in the A/A group and 3 patients (2.4%) in the P/A group experienced serious TEAEs that were considered unrelated to the study drug. Severe hypoglycaemia was reported by 1 patient in the P/A group during the double-blind phase.
The overall incidence of TEAEs after initiation of trelagliptin was 87.9% (n = 102) in the A/A group and 78.2% (n = 93) in the P/A group (Table S4 in File S1). The incidence of serious TEAEs was 13.8%
(n = 16) and 7.6% (n = 9) in the A/A and P/A groups, respectively. In the A/A group, 1 patient died by suicide, which was assessed to be unrelated to the study drug. In the P/A group, 1 patient had a serious TEAE of chronic myeloid leukaemia, observed during the open-label phase, which was assessed to be related to the study drug. No severe hypoglycaemia was reported after initiation of trelagliptin. The incidence of TEAEs occurring ≥2% in either the A/A or the P/A group after initiation of trelagliptin is reported in Table S6 in File S1.
A total of 12 patients (10.3%) in the A/A group and 11 patients Abbreviations: A/A group, trelagliptin 100 mg with insulin; P/A group, placebo tablet with insulin; HbA1c, haemoglobin A1c; SD, standard deviation
